Core Insights - Paysign, Inc. reported a significant revenue growth of 40.5% for the full year 2025, driven primarily by patient affordability solutions, which saw a remarkable increase of 167.8% in pharma revenue [2][4][5] Financial Performance - Full-year 2025 total revenues reached $82.02 million, an increase of $23.64 million from $58.38 million in 2024 [5] - Net income for 2025 was $7.55 million, or $0.13 per diluted share, compared to $3.82 million, or $0.07 per diluted share in 2024, marking a 97.9% increase [10] - Adjusted EBITDA for 2025 was $19.94 million, up 107.3% from $9.62 million in 2024, with diluted Adjusted EBITDA per share increasing to $0.33 from $0.17 [10][2] Revenue Breakdown - Plasma revenue for 2025 was $45.62 million, a 4.0% increase from $43.88 million in 2024, attributed to the addition of 115 net plasma centers [5] - Pharma revenue surged to $33.89 million, up 167.8% from $12.65 million in 2024, due to the launch of 55 net patient affordability programs [5][4] - Patient affordability claim volume increased over 79% during 2025 compared to the previous year [2] Operational Highlights - The company exited 2025 with 595 plasma centers, up from 480 at the end of 2024, contributing to the overall revenue growth [5] - Gross profit margin improved to 59.4% in 2025 from 55.1% in 2024, reflecting better operational efficiency [7] - Operating margin for 2025 was 9.0%, significantly higher than 1.7% in 2024 [8] Balance Sheet and Cash Flow - As of December 31, 2025, unrestricted cash was $21.07 million, with zero debt, and restricted cash increased by 29.0% to $143.92 million [14][15] - The company repurchased 100,000 shares of common stock for $376 thousand during the year [2] 2026 Outlook - For 2026, Paysign expects revenue between $106.5 million and $110.5 million, representing a year-over-year growth of 30.0% to 35.0% [17] - Gross profit margins are anticipated to be between 60.0% to 62.0%, driven by increased contributions from the pharma patient affordability business [18] - Net income is projected to nearly double compared to 2025, reaching between $13.0 million and $16.0 million, or $0.21 to $0.26 per diluted share [18]

Financial Data and Key Metrics Changes - In fiscal year 2025, the company generated EUR 468 million in free cash flow, an increase of over EUR 200 million year-over-year, reflecting a focus on capital discipline [4] - Revenue reached EUR 7,524 million, representing a 7% increase over the previous year and a 9.1% increase on a like-for-like basis [4] - Adjusted EBITDA reached EUR 1,825 million, a 5.6% year-over-year increase, while on a like-for-like basis, it increased by close to 12% [5][36] - The leverage ratio improved to 4.2 times, a reduction of 4 points from the prior year [6] Business Line Data and Key Metrics Changes - The Biopharma segment grew 8.4% for the year on a reported basis and 10.9% on a like-for-like basis, driven by the immunoglobulin franchise, which saw a 14.7% year-over-year increase [12][13] - Albumin revenues declined by 5.1% year-over-year due to market pressures in China, although positive momentum was noted in the U.S. and other regions [16] - The Alpha-1 and specialty proteins portfolio saw a full-year growth of 1.4% or 3.8% on a like-for-like basis [18] Market Data and Key Metrics Changes - In China, albumin demand declined amid government cost controls, but the company managed to outperform the market through a partnership with Shanghai RAAS [7] - The U.S. remains the most important IgG market, with the company being the only scale plasma company with a fully integrated end-to-end value chain [10] Company Strategy and Development Direction - The company aims to prioritize profitability and cash flow generation while reducing leverage, with key projects in Egypt and Canada expected to redefine the plasma industry [10][23] - The focus for 2026 includes balancing growth across key proteins and enhancing margin improvements [9][50] - The company is committed to a localized business model to mitigate geopolitical risks and ensure supply chain resilience [11][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate complex geopolitical and macroeconomic environments, highlighting the strength and resilience of the business model [3] - The company is optimistic about achieving margin expansion goals and continues to advance differentiated therapies to the market [8][54] Other Important Information - The company successfully launched Prufibry in Europe and plans to launch FESILTY in the U.S. in the first half of 2026 [8][20] - The strategic partnership in Egypt has achieved EMA approval for Egyptian-sourced plasma, marking a significant milestone for the company [28][30] Q&A Session Summary Question: Is 2026 a specific year where growth is differing from the capital market target? - Management clarified that the focus is on optimizing the quality of EBITDA growth rather than prioritizing revenue growth for 2026 [56][58] Question: What are the internal levers to improve profitability? - Management indicated that balancing growth in IG and albumin, along with driving efficiencies in manufacturing and plasma collection, are key levers for improving profitability [69][72] Question: What is the status of the Haema BPC buyback? - The timing of the Haema BPC buyback will be determined by the board, with potential execution expected in 2026 or 2027 [73]

Financial Data and Key Metrics Changes - In fiscal year 2025, the company generated EUR 468 million in free cash flow, an increase of over EUR 200 million year-over-year, reflecting a focus on capital discipline [4][6] - Revenue reached EUR 7,524 million, representing a 7% increase over the previous year and a 9.1% increase on a like-for-like basis [4][5] - Adjusted EBITDA reached EUR 1,825 million, a 5.6% year-over-year increase, with a like-for-like increase of close to 12% [5][36] - The leverage ratio improved to 4.2x, a reduction from 4.6x at the end of 2024 [6][38] Business Line Data and Key Metrics Changes - The Biopharma segment grew 8.4% for the year on a reported basis and 10.9% on a like-for-like basis, driven by the immunoglobulin franchise which saw a 14.7% year-over-year increase [12][14] - Albumin revenues declined by 5.1% year-over-year due to market pressures in China, although positive momentum was observed in the U.S. and other regions [16][17] - The Alpha-1 and specialty proteins portfolio saw a full-year growth of 1.4% or 3.8% on a like-for-like basis [18] Market Data and Key Metrics Changes - In China, albumin demand declined amid government cost controls, but the company managed to outperform the market through a partnership with Shanghai RAAS [7][16] - The U.S. remains the most important market for immunoglobulin, with the company being the only scale plasma company with a fully integrated end-to-end value chain [10][24] Company Strategy and Development Direction - The company aims to prioritize profitability and cash flow generation while reducing leverage, with key projects in Egypt and Canada expected to redefine the plasma industry [10][23] - The focus for 2026 includes balancing growth across key proteins and enhancing margin improvements [9][49] - The strategic partnership in Egypt is seen as a game-changer, allowing for the commercialization of plasma-derived therapies sourced from Egyptian plasma [28][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning and resilience amid geopolitical and macroeconomic challenges [3][11] - The company is focused on optimizing EBITDA growth quality and balancing immunoglobulin and albumin growth [58][60] - The fundamentals of the business remain sound, with a commitment to long-term vision and value creation for shareholders [53][54] Other Important Information - The company achieved a significant credit rating improvement, with S&P moving ratings from B flat stable to BB- stable [45] - The company plans to refinance its 2027 maturities, with preparations in advanced stages [46] Q&A Session Summary Question: Is 2026 a year where growth differs from capital market targets? - Management indicated that revenue growth is not a priority for 2026, focusing instead on optimizing EBITDA quality [58][60] Question: Potential EBITDA guidance for 2026? - Management confirmed that the estimated EBITDA guidance for 2026 aligns with the analyst's calculations, suggesting a range of EUR 1.9 billion to EUR 1.97 billion [63][64] Question: What are the levers for improving profitability? - Management explained that balancing growth in IG and albumin, along with driving efficiencies in manufacturing and plasma collection, are key levers for improving profitability [69][72] Question: Update on Haema BPC buyback? - Management stated that the timing of the buyback will be determined by the board, with expectations for execution in 2026 or 2027 [73]

Financial Data and Key Metrics Changes - In fiscal year 2025, the company generated EUR 468 million in free cash flow, an increase of over EUR 200 million year-over-year, reflecting a focus on capital discipline [4] - Revenue reached EUR 7,524 million, representing a 7% increase over the previous year and a 9.1% increase on a like-for-like basis [4] - Adjusted EBITDA reached EUR 1,825 million, a 5.6% year-over-year increase, with a like-for-like increase of close to 12% [5][34] - The leverage ratio improved to 4.2 times, a reduction of 0.4 times from the previous year [5][38] Business Line Data and Key Metrics Changes - The Biopharma segment grew 8.4% for the year on a reported basis and 10.9% on a like-for-like basis, driven by the immunoglobulin franchise, which saw a 14.7% year-over-year increase [11] - Albumin revenues declined by 5.1% year-over-year due to market pressures in China, although the company outperformed the market through its partnership with Shanghai RAAS [15] - The Alpha-1 and specialty proteins portfolio saw a full-year growth of 1.4% or 3.8% on a like-for-like basis [16] Market Data and Key Metrics Changes - In the U.S., the company stands as the only scale plasma company with a fully integrated end-to-end value chain, which is crucial for the IgG market [9] - In Canada, the share of IG self-sufficiency increased from 15% to around 30% in 2025, with plans for further expansion [26] - The strategic partnership in Egypt has achieved EMA approval for Egyptian-sourced plasma, marking a significant milestone for the company [27] Company Strategy and Development Direction - The company aims to prioritize profitability and cash flow generation while reducing leverage, focusing on key projects in Egypt and Canada [9] - The local-for-local business model has proven resilient against macroeconomic challenges, allowing the company to navigate tariff impacts effectively [8] - The company is committed to enhancing its vertical integration and self-sufficiency in key markets, which is expected to provide a competitive advantage [22][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning and fundamentals, emphasizing the resilience of the plasma industry amid geopolitical shifts [10][53] - The focus for 2026 will be on margin expansion and controlled growth, with a clear strategy to balance growth across IG and albumin [49] - The company is optimistic about the long-term potential of its strategic partnerships and the ability to meet evolving market demands [32][53] Other Important Information - The company achieved a significant credit rating improvement, with S&P upgrading its rating from B flat stable to BB- stable [45] - The company plans to refinance its 2027 maturities, with preparations already in advanced stages [46] Q&A Session Summary Question: Is 2026 a specific year where growth differs from capital market targets? - Management clarified that revenue growth is not a priority for 2026, focusing instead on optimizing EBITDA quality and leveraging market share gains in the U.S. [56][57] Question: What is the potential EBITDA guidance for 2026? - Management indicated that the EBITDA guidance for 2026 could be around EUR 1.9 billion to EUR 1.97 billion, depending on margin assumptions [63][64] Question: What are the internal levers to improve profitability? - Management explained that the focus is on balancing growth in IG and albumin while driving efficiencies in manufacturing and plasma collection [68][72] Question: What is the status of the Haema BPC buyback? - Management stated that the timing of the buyback will be determined by the board, with potential execution in 2026 or 2027 [73]